At the annual American College of Allergy Asthma and Immunology meeting being held in Seattle, Washington this November, the results from a study on a peanut immunotherapy product were reported on. The study advances our knowledge regarding the potential treatments for peanut allergy and further validates the effectiveness of medically supervised Oral Immunotherapy.
Peanut allergy is common, affecting approximately one in 50 American children. Peanut allergic reactions are thought to cause more deaths from anaphylaxis than any other food allergen. The traditional approach for the treatment of peanut allergy is to avoid peanuts, even as a mixed ingredient of another food, and to carry emergency medicine (including an epinephrine autoinjector) at all time. These restrictions and the associated fear of triggering an allergic reaction usually result in a significant impairment of quality of life.